Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects (OPTIMUM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03561259
Recruitment Status : Recruiting
First Posted : June 19, 2018
Last Update Posted : June 1, 2021
Sponsor:
Information provided by (Responsible Party):
Jubilant DraxImage Inc.

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of 131I-MIBG in combination with Vorinostat in patients with Recurrent or Progressive neuroblastoma

Condition or disease Intervention/treatment Phase
Neuroblastoma Neuroectodermal Tumors Neoplasms Drug: 131I-MIBG Drug: 131-MIBG + Vorinostat Phase 2

Expanded Access : An investigational treatment associated with this study is available outside the clinical trial.   More info ...

Detailed Description:

OPTIMUM (MIBG 2014-01) is a Phase II, Two arm, non-randomized, open-label study of therapeutic 131I-iobenguane (131I-MIBG) as single agent or in combination with Vorinostat for the treatment of neuroblastoma. The study will be conducted in male and female subjects, greater than 1 year of age, with iobenguane avid, who have recurrent or progressive disease, regardless of overall response to frontline therapy, where frontline therapy includes a minimum of 4 cycles of induction therapy at any time prior to enrollment, high-risk neuroblastoma.

Subjects who are eligible for combination treatment will receive vorinostat 180 mg/m2/dose (maximum dose 400 mg) once daily for 14 days (Day -1 to Day 12) continuously.

Subjects will receive 18 mCi/kg of 131I-MIBG intravenously on Day 1.

If the subject qualifies, the subject will receive the second treatment course of 131I-MIBG in combination with vorinostat or 131I-MIBG alone (no sooner than 6 weeks following first treatment course). Subject must have an overall response of stable disease or better, as assessed by the Investigator, and meet certain predefined criteria to receive the second course of treatment.

Following a screening period of up to 4 weeks, the duration in the study treatment phase for an individual subject, who receives two treatments, is up to 26 weeks. For an individual subject, who receives one treatment only, the duration of the treatment phase is 16 weeks. In addition, there is a 2-year follow-up after the treatment phase, during which assessments will be performed to assess disease progression, as well as record adverse events.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Intervention Model Description: Two-arm, non-randomized, open-label study.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Open Label, Two-Arm Study of Therapeutic Iobenguane (131I) as Single Agent or in Combination With Vorinostat for Recurrent or Progressive High- Risk Neuroblastoma Subjects (OPTIMUM TRIAL)
Actual Study Start Date : October 21, 2019
Estimated Primary Completion Date : April 1, 2023
Estimated Study Completion Date : April 2025


Arm Intervention/treatment
Experimental: 131I-MIBG
131I-MIBG
Drug: 131I-MIBG
Subjects will receive 18 mCi/kg of 131I-MIBG administered over 1.5 to 2 hours on Day 1 either a central line or a peripheral intravenous catheter. The maximum absolute dose of 131I-MIBG is determined by institution therapeutic limits and will not exceed 1,000 mCi. Subjects with an overall response of stable disease or better as assessed by the Investigator, and who meet certain protocol predefined criteria, may receive a second 18 mCi/kg 131I-MIBG treatment no sooner than 6 weeks following the first treatment.
Other Names:
  • I-131 meta-iodobenzylguanidine
  • Iobenguane I-131 MIBG Injection

Experimental: 131I-MIBG + Vorinostat
131I-MIBG + Vorinostat
Drug: 131-MIBG + Vorinostat
Subjects will receive vorinostat 180 mg/m2/dose (maximum dose 400 mg) once daily by mouth, NG, or G-tube on days -1 to +12 (14 total doses) for 14 days continuously. The 131I-MIBG treatment will be administered on day 1 via either a central line or a peripheral intravenous catheter over 1.5 to 2 hours. On day 1 of therapy, vorinostat should be taken 1 hour prior to the start of the 131I-MIBG infusion. Subjects with an overall response of stable disease or better, as assessed by the Investigator and who meet certain predefined criteria, may receive a second course of 18 mCi/kg 131I-MIBG combined with vorinostat (180 mg/m2) no sooner than 6 weeks following the first therapeutic 131I-MIBG treatment.




Primary Outcome Measures :
  1. Overall Response [ Time Frame: 6 weeks after the last 131I-MIBG treatment which will either be the first or the second treatment course (131I-MIBG + vorinostat) and a confirmatory assessment at least 6 weeks thereafter (at least 12 weeks from the end of treatment) ]
    Overall response (Yes/No) is based on the International Neuroblastoma Response Criteria (INRC, published 2017). The INRC will be calculated based on 123I-iobenguane scans, CT/MRI, and bone marrow biopsies and aspirates. A "Yes" is defined as complete response, partial response or minor response. A "No" response is defined as stable disease or progressive disease.


Secondary Outcome Measures :
  1. Overall Response at 6 weeks after 131I-MIBG treatment [ Time Frame: 6 weeks after the last 131I-MIBG treatment (first or second treatment of 131I-MIBG + vorinostat). ]
    The Revised INRC overall response (yes/no) defined as complete response, partial response, or minor response 6 weeks after the last131I-MIBG treatment which will either be the first treatment or the second treatment.

  2. Durability of Effect of Overall Response (Yes/No) [ Time Frame: For all tumour assessment data collected throughout the study (up to the end of the 2-year follow-up)(131I-MIBG + vorinostat). ]
    Durability of effect with the INRC will be assessed as INRC for all tumor assessment data available including any data collected beyond 12 weeks after the last 131I-MIBG treatment which will either be the first treatment or the second treatment.

  3. Relative Curie Extension Score [ Time Frame: 6 weeks after the last 131I-MIBG treatment which will either be the first or the second treatment course (131I-MIBG + vorinostat) ]
    Relative Curie Extension Score 6 weeks after the last MIBG 131I treatment, which will either be the first treatment or the second treatment.

  4. Durability of Effect of Relative Curie Extension Score [ Time Frame: For all tumour assessment data collected throughout the study for both arms (up to the end of the 2-year follow-up). ]
    Durability of effect with the Relative Curie Extension Score will be assessed as the score for all tumor assessment data available including any data collected beyond 12 weeks after the last MIBG 131I treatment, which will either be the first treatment or the second treatment. The Relative Curie Extension Score will be calculated using the Baseline (Visit 2) Absolute Curie Extension Score. The Curie Extension Scores will be calculated from the results of the (123I) iobenguane scans.


Other Outcome Measures:
  1. Incidence of Adverse Events (CTCAE Version 5.0) [ Time Frame: Up to 22 weeks ]
    Adverse events as graded according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0

  2. Incidence of Serious Adverse Events [ Time Frame: Through study completion, up to 2.5 years. ]
    Percentage of subjects with hematological and nonhematological toxicities. Any relationship between the whole body radiation absorbed dose and nonhematological SAEs will also be assessed;

  3. Whole Body Radiation Dose [ Time Frame: After each 131I-MIBG treatment for up to 120 hours. ]
    To assess radiation safety in terms of any potential relationship between the whole body radiation absorbed dose and nonhematological serious adverse events (SAEs)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects with a diagnosis of iobenguane avid, high-risk neuroblastoma based on Revised INRC criteria at the time of study enrollment with recurrent or progressive disease at any time prior to enrollment, regardless of overall response to frontline therapy, where frontline therapy includes a minimum of 4 cycles of induction therapy at any time prior to enrollment.
  2. May have had prior 131I-MIBG therapy, provided:

    1. It has been at least 6 months from the date of last 131I-MIBG ;
    2. Response was other than progressive disease on first restaging after 131I-MIBG ;
    3. Prior 131I-MIBG was given as monotherapy and not in combination with systemic anticancer agents;
    4. Cumulative lifetime dose of 131I-MIBG at enrollment does not exceed 18 mCi/kg.
  3. All soft tissue lesions identified on CT/MRI scans must be iobenguane avid lesions on an (123I)-iobenguane scan, or

    1. any progressive non-iobenguane avid lesion is proven by biopsy to be a non-neuroblastoma lesion.
    2. any other non-avid lesion is comprised of a fibrotic or scarred mass as shown by routine imaging and confirmed by the investigator.
  4. Adequate cryopreserved autologous peripheral blood stem cells or bone marrow (at least 2 aliquots of 2.0 × 10exp6 CD34/kg at the time of study enrollment).
  5. If a male, must agree to use an adequate contraception method as deemed appropriate by the Investigator (e.g., vasectomy, condoms) or partner using effective contraception and to not donate sperm during the study and for 90 days after receiving the last dose of study drug.
  6. If a female of childbearing potential, have a negative serum pregnancy test result prior to each dosing and, if sexually active, be practicing an effective method of birth control [e.g., intrauterine device, double-barrier method (i.e., diaphragm, or a cervical cap) with intravaginal spermicidal foam, cream or gel], or male partner sterilization throughout the study.
  7. Age at study entry ≥1 year.
  8. Previous platelet transfusions are permitted, as long as the subject has a platelet count ≥50,000/μL without transfusion support for at least 1 week.
  9. Subjects must have a minimum pulse oximetry measurement of at least 94% at baseline.
  10. An absolute neutrophil count ≥750/μL without growth factor for 5 days.
  11. Liver function parameter results: total bilirubin ≤2 × upper limit of normal for age, and Serum alanine aminotransferase (glutamic-pyruvic transaminase) and serum aspartate aminotransferase (glutamic-oxaloacetic transaminase) ≤ 10 times the upper limit of normal (for all sites, the upper limit of normal for alanine aminotransferase is defined as 45 U/L).
  12. Normal thyroid function as measured by T4 or TSH or have abnormal results that are not considered clinically important by the Investigator or may be receiving levothyroxine.
  13. Cardiac Function: shortening fraction of ≥ 27% by echocardiogram or ejection fraction ≥ 50% documented by echocardiogram or radionuclide angiogram within 1 month prior to Visit 1 (Baseline).
  14. Karnofsky Performance Status (for subjects >16 years of age) or the Lansky Performance Status Performance Status (for subjects 1 to 16 years of age) ≥50%.
  15. Full recovery from the toxic effects of any prior therapy.
  16. Coagulation Function:

    1. International Normalized Ratio (INR) < 1.5
    2. Partial thromboplastin time (PTT) < 1.5 times upper limit of normal.

Exclusion Criteria:

  1. Subjects within 5 half-lives after any antibody-based immunotherapy, or have not recovered from effects of any biologic therapy.
  2. Subjects <12 weeks after myeloablative therapy with autologous stem cell transplant.
  3. Subjects who have had an allogeneic stem cell treatment less than 4 months from Visit 1 are excluded. Those who have received allogeneic stem cell treatment more than 4 months from Visit 1 must have recovered and have no active graft versus host disease (GVHD) to be eligible.
  4. Subjects must not have received radiation for a minimum of 2 weeks prior to study enrollment. Subjects whose only site(s) of disease have been radiated are eligible as long as the subject has MIBG avidity 2 weeks after completion of radiation. A minimum of 12 weeks prior to study enrollment is required following prior large field radiation therapy (ie, craniospinal, whole abdominal, total lung, > 50% marrow space)
  5. History of total body irradiation.
  6. Subjects do not have adequate renal function defined as GFR ≥ 70 mL/min/1.73 m2 either by creatinine clearance or radioisotope direct measurement or by calculation with the Schwartz formula
  7. Subjects who are on hemodialysis.
  8. Pregnancy or breastfeeding.
  9. Significant active infections including active hepatitis B, or hepatitis C infection, or known infection with human immunodeficiency virus (HIV) (testing for HIV is not required prior to study entry).
  10. Clinically important cardiac, pulmonary, and hepatic impairment.
  11. Vorinostat treatment exclusion criteria (subjects, who meet any one of these criteria and otherwise meet eligibility criteria, are still eligible for 131I-MIBG monotherapy)

    1. Since valproic acid has HDAC inhibitory activity, patients must not have received valproic acid within 30 days of study entry.
    2. Since vorinostat may prolong the QT interval, patients must not be receiving other medications known to prolong the QT interval at the time of study entry . Pentamidine must not have been received within 1 week of study enrollment.
    3. Patients with a history of deep venous thrombosis that was not associated with the presence of a central venous catheter.
    4. Patients who are receiving Coumadin.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03561259


Contacts
Layout table for location contacts
Contact: Norman LaFrance, MD,FACP 267-475-2192 MIBGclinicaltrials@jdi.jubl.com
Contact: Suzanne Bissonnette 215-406-0127 ext 7027 SBissonnette@jubl.com

Locations
Layout table for location information
United States, California
UCSF Pediatric Hematology/Oncology Recruiting
San Francisco, California, United States, 94158
Contact: Debbie Lara    415-476-2218    Debbie.deLara@ucsf.edu   
Principal Investigator: Kieuhoa Vo, MD         
United States, Colorado
Children's Hospital Colorado Recruiting
Aurora, Colorado, United States, 80045
Contact: Astrid Eder    720-777-8531    astrid.eder@coloradochildrens.org   
Principal Investigator: Margaret Macy, MD         
United States, Florida
Nemours Children's Specialty Care Recruiting
Jacksonville, Florida, United States, 32207
Contact: Manisha M Bansal, MD    904-697-3793    Manisha.Bansal@nemours.org   
Principal Investigator: Manisha Bansal, MD         
United States, Illinois
University of Chicago Medical Center Recruiting
Chicago, Illinois, United States, 60637
Contact: Melissa Z Marx, MPH    773-702-2927    lzeilner@peds.bsd.uchicago.edu   
Principal Investigator: Ami V Desai, MD         
United States, Iowa
University of Iowa Hospitals and Clinics Recruiting
Iowa City, Iowa, United States, 52242
Contact: Roxane Mitten    319-356-1212    roxanne-mitten@uiowa.edu   
Principal Investigator: Mariko Sato, MD, PhD         
United States, Massachusetts
Dana-Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Catherine M Clinton, MS    617-632-5556    Catherine_clinton@dfci.harvard.edu   
Principal Investigator: Suzanne Shusterman, MD         
United States, Minnesota
University of Minnesota Recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Ashley Schempp, MPH    612-625-9340    john3587@umn.edu   
Principal Investigator: Emily Greengard, MD         
United States, Missouri
Washington University Medical Center in St. Louis Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Sally Jones, MA, CCRP    314-454-4353    jones_s@wustl.edu   
Principal Investigator: Frederick Huang, MD         
United States, North Carolina
Carolinas Medical Center/Levine Children's Hospital (Atrium Health) Recruiting
Charlotte, North Carolina, United States, 28203
Contact: Katherine Farmer    704-641-7350    Katherine.Farmer@atriumhealth.org   
Principal Investigator: Javier E Osterheld, MD         
United States, Ohio
Cincinnati Children's Hospital Medical Center Recruiting
Cincinnati, Ohio, United States, 45229
Contact: Lori Backus    513-636-2047    lori.backus@cchmc.org   
Principal Investigator: Brian Weiss, MD         
United States, Pennsylvania
The Children's Hospital of Philadelphia Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Yael Mosse, MD    215-590-0965    mosse@email.chop.edu   
Contact: Jennifer Saggio       SAGGIO@email.chop.edu   
Principal Investigator: Yael Mosse, MD         
Children's Hospital of Pittsburgh Recruiting
Pittsburgh, Pennsylvania, United States, 15224
Contact: Jean M Tersak, MD    412-365-0323    jean.tersak@chp.edu   
Principal Investigator: Jean Tersak, MD         
United States, Texas
University of Texas Southwestern Medical Center, Children's Health Recruiting
Dallas, Texas, United States, 75235
Contact: Beverly Kleiber, PhD, CCRP    214-456-1003    beverly.kleiber@childrens.com   
Principal Investigator: Tanya Watt, MD         
Cook Children's Hematology/Oncology Center Recruiting
Fort Worth, Texas, United States, 76104
Contact: Juli Ramirez    682-885-2580    juli.ramirez@cookchildrens.org   
Principal Investigator: Meaghan Granger, MD         
Texas Children's Hospital Recruiting
Houston, Texas, United States, 77030
Contact: Akudo Anyanwu:    832-824-4167    aanyanw@texaschildrens.org   
Principal Investigator: Jennifer Foster, MD         
United States, Washington
Seattle Children's Hospital Recruiting
Seattle, Washington, United States, 98105
Contact: Christine Goetz, BA,CCRC    206-884-1149    christine.goetz@seattlechildrens.org   
Principal Investigator: Navin R Pinto, MD         
Sponsors and Collaborators
Jubilant DraxImage Inc.
Investigators
Layout table for investigator information
Study Director: Norman LaFrance, MD,FACP Jubilant DraxImage Inc.
Layout table for additonal information
Responsible Party: Jubilant DraxImage Inc.
ClinicalTrials.gov Identifier: NCT03561259    
Other Study ID Numbers: MIBG 2014-01
First Posted: June 19, 2018    Key Record Dates
Last Update Posted: June 1, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jubilant DraxImage Inc.:
Iobenguane Avid High-risk Neuroblastoma
3-Iodobenzylguanidine
Radiopharmaceutical
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroblastoma
Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
Neuroectodermal Tumors, Primitive, Peripheral
Neoplasms, Neuroepithelial
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Vorinostat
3-Iodobenzylguanidine
Antineoplastic Agents
Histone Deacetylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Radiopharmaceuticals